
USD
$0.00
(0.00%
)At Close (As of Oct 24, 2025)
$464.66B
Market Cap
18.6
P/E Ratio
10.35
EPS
$194.48
52 Week High
$137.37
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $61B |
| Total Revenue | $89B |
| Cost Of Revenue | $27B |
| Costof Goods And Services Sold | $27B |
| Operating Income | $22B |
| Selling General And Administrative | $22B |
| Research And Development | $17B |
| Operating Expenses | $67B |
| Investment Income Net | - |
| Net Interest Income | $577M |
| Interest Income | $1.3B |
| Interest Expense | $755M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $7.3B |
| Income Before Tax | $17B |
| Income Tax Expense | $2.6B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $14B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $17B |
| Ebitda | $25B |
| Net Income | $14B |
| Field | Value (USD) |
|---|---|
| Total Assets | $180B |
| Total Current Assets | $56B |
| Cash And Cash Equivalents At Carrying Value | $24B |
| Cash And Short Term Investments | $24B |
| Inventory | $12B |
| Current Net Receivables | $15B |
| Total Non Current Assets | $124B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $38B |
| Intangible Assets Excluding Goodwill | $38B |
| Goodwill | $44B |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $417M |
| Other Current Assets | - |
| Other Non Current Assets | - |
| Total Liabilities | $109B |
| Total Current Liabilities | $50B |
| Current Accounts Payable | $10B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $6B |
| Total Non Current Liabilities | $58B |
| Capital Lease Obligations | - |
| Long Term Debt | $31B |
| Current Long Term Debt | $6B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $37B |
| Other Current Liabilities | $30B |
| Other Non Current Liabilities | $18B |
| Total Shareholder Equity | $71B |
| Treasury Stock | - |
| Retained Earnings | - |
| Common Stock | - |
| Common Stock Shares Outstanding | $2.4B |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $24B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $7.3B |
| Capital Expenditures | $4.4B |
| Change In Receivables | - |
| Change In Inventory | -$1.1B |
| Profit Loss | - |
| Cashflow From Investment | -$19B |
| Cashflow From Financing | -$3.1B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $12B |
| Dividend Payout Common Stock | $12B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$2.4B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $14B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $61B |
| Total Revenue | $89B |
| Cost Of Revenue | $27B |
| Costof Goods And Services Sold | $27B |
| Operating Income | $22B |
| Selling General And Administrative | $22B |
| Research And Development | $17B |
| Operating Expenses | $67B |
| Investment Income Net | - |
| Net Interest Income | $577M |
| Interest Income | $1.3B |
| Interest Expense | $755M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $7.3B |
| Income Before Tax | $17B |
| Income Tax Expense | $2.6B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $14B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $17B |
| Ebitda | $25B |
| Net Income | $14B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-11-25 |
| Declaration Date | 2025-10-14 |
| Record Date | 2025-11-25 |
| Payment Date | 2025-12-09 |
| Amount | 1.3 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Johnson & Johnson (JNJ) is a premier American multinational corporation, founded in 1886, that operates across three main segments: medical devices, pharmaceuticals, and consumer health products. Renowned for its commitment to innovation and quality, J&J plays a pivotal role in the global healthcare landscape and is consistently recognized as one of the world's most valuable enterprises. As a prominent member of the Dow Jones Industrial Average with a coveted AAA credit rating, the company exemplifies financial stability and robust operational performance. Positioned 36th on the Fortune 500 list, J&J is well-equipped to drive sustainable growth while maintaining its status as a trusted provider of health solutions worldwide.